Celiac Disease in Children, Growth Delay, Health, Subjective, Pediatric Disorder
Conditions
Keywords
screening
Brief summary
The investigators aim to examine the feasibility of incorporating serological celiac disease (CD) screening into general pediatric outpatient clinics in Sweden and through structured monitoring examine the effects of diagnosing and treating screening-detected CD. Screening will be tailored to general pediatric outpatient clinics in the Gothenburg metropolitan area with the goal to screen 1000 children over four months. Screening for CD will be carried out by measuring tissue transglutaminase autoantibodies (TGA) in blood. Children who are persistently TGA positive will be enrolled into a 6-12-month follow-up protocol responsible for diagnosing CD, installation of gluten-free diet and to assess their short-term impact upon the child's wellbeing. Other components to assess include (I) the feasibility to incorporate CD screening into busy pediatric practices; (II) parental/child interest in, and satisfaction with, participating in a CD screening program and (III) identifying key considerations for a possible scaled-up, broad-based, CD screening.
Interventions
DIAGNOSTIC_TESTtissue transglutaminase autoantibodies
celiac disease-specific autoantibodies
Sponsors
Vastra Gotaland Region
Sahlgrenska University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 2-17 years old * Patient at pediatric outpatient clinics in Gothenburg metro area * Parental and adolescent consent to screening
Exclusion criteria
for serological screening: * Established celiac disease diagnosis * Type 1 diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants diagnosed with celiac disease | Assessed after 6-12 months of follow-up | Celiac disease diagnosed according to European pediatric (ESPGHAN) guidelines |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants identified with celiac disease autoimmunity | Assessed after performed two tests of TTG (apprx. 1-2 months after enrollment) | Celiac disease autoimmunity defined by having two consecutive positive tests for tissue transglutaminase (TTG) autoantibodies |
Countries
Sweden
Outcome results
None listed